(2017) The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomedicine & Pharmacotherapy. pp. 620-627. ISSN 0753-3322
Full text not available from this repository.
Abstract
Glaucoma represents several optic neuropathies leading to irreversible blindness through progressive retinal ganglion cell (RGC) loss. Reduction of intraocular pressure (IOP) is known as the only modifiable factor in the treatment of this disorder. Application of exogenous cannabinoids to lower IOP has attracted attention of scientists as potential agents for the treatment of glaucoma. Accordingly, neuroprotective effect of these agents has been recently described through modulation of endocannabinoid system in the eye. In the present work, pertinent information regarding ocular endocannabinoid system, mechanism of exogenous cannabinoids interaction with the ocular endocannabinoid system to reduce IOP, and neuroprotection property of cannabinoids will be discussed according to current scientific literature. In addition to experimental studies, bioavailability of cannabinoids, clinical surveys, and adverse effects of application of cannabinoids in glaucoma will be reviewed. (C) 2016 Elsevier Masson SAS. All rights reserved.
| Item Type: | Article |
|---|---|
| Keywords: | Cannabis sativa Endocannabinoid system Glaucoma Intraocular pressure Marijuana Neuroprotection pressure-induced ischemia retinal ganglion-cells intraocular-pressure endocannabinoid system rat model abnormal cannabidiol normotensive rabbits parkinsons-disease multiple-sclerosis epithelial-cells Research & Experimental Medicine Pharmacology & Pharmacy |
| Divisions: | |
| Page Range: | pp. 620-627 |
| Journal or Publication Title: | Biomedicine & Pharmacotherapy |
| Journal Index: | ISI |
| Volume: | 86 |
| Identification Number: | https://doi.org/10.1016/j.biopha.2016.11.106 |
| ISSN: | 0753-3322 |
| Depositing User: | مهندس مهدی شریفی |
| URI: | http://eprints.bmsu.ac.ir/id/eprint/4563 |
Actions (login required)
 |
View Item |